Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | HTR3A | P46098 | 7/20 | 0.46 |
| ▸ | HTR3E | A5X5Y0 | 4/20 | 0.46 |
| ▸ | HTR3B | O95264 | 4/20 | 0.46 |
| ▸ | HTR3D | Q70Z44 | 4/20 | 0.46 |
| ▸ | HTR3C | Q8WXA8 | 4/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Maleic Acid SCHEMBL9757972 | 0.94 | KDM4E (0.48) | MEN1KMT2AHTR3AHTR3EHTR3B | |
| SCHEMBL8939998 | 0.78 | PKM (0.52) | MEN1KMT2AHTR3AHTR3EHTR3B | |
| SCHEMBL9201788 | 0.76 | MEN1 (0.55) | MEN1KMT2A | |
| SCHEMBL7269216 | 0.74 | HTR3A (0.51) | MEN1KMT2AHTR3AHTR3EHTR3B | |
| SCHEMBL7270849 | 0.74 | HTR3A (0.51) | MEN1KMT2AHTR3AHTR3EHTR3B | |
| SCHEMBL7276361 | 0.74 | HTR3A (0.51) | MEN1KMT2AHTR3AHTR3EHTR3B | |
| SCHEMBL7269263 | 0.74 | HTR3A (0.51) | MEN1KMT2AHTR3AHTR3EHTR3B | |
| SCHEMBL7269268 | 0.74 | HTR3A (0.51) | MEN1KMT2AHTR3AHTR3EHTR3B | |
| SCHEMBL7270520 | 0.74 | HTR3A (0.51) | MEN1KMT2AHTR3AHTR3EHTR3B | |
| SCHEMBL8939969 | 0.74 | HTR3A (0.46) | MEN1KMT2AHTR3AHTR3EHTR3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5364863-A | Treatment of migraine, emesis, schizophrenia, anxiety, gastrointestinal disorders | ELI LILLY AND COMPANY (US) | 1994-11-15 | — | — | US | claimed |
| US-5563148-A | BICYCLIC ESTERS OR AMIDES; USED IN TREATING MIGRAINE, EMESIS, GASTROINTESTINAL DISORDERS, SCHIZOPHRENIA OR ANXIETY IN MAMMALS | ELI LILLY AND COMPANY (US) | 1996-10-08 | — | — | US | disclosed |
| EP-0307172-B1 | Improvements in or relating to specific 5-HT3 antagonists | LILLY CO ELI (US) | 1995-10-11 | — | — | EP | disclosed |
| US-5442078-A | Intermediates for specific 5-HT3 antagonists | ELI LILLY AND COMPANY (US) | 1995-08-15 | — | — | US | disclosed |
| US-5364863-A | Treatment of migraine, emesis, schizophrenia, anxiety, gastrointestinal disorders | ELI LILLY AND COMPANY (US) | 1994-11-15 | — | — | US | disclosed |
| US-4921982-A | 5-halo-2,3-dihydro-2,2-dimethylbenzofuran-7-carboxylic acids useful as intermediates for 5-HT3 antagonists | ELI LILLY AND COMPANY (US) | 1990-05-01 | — | — | US | disclosed |
| EP-0307172-A2 | Improvements in or relating to specific 5-HT3 antagonists | ELI LILLY AND COMPANY (US) | 1989-03-15 | — | — | EP | disclosed |